WS10.04 Analyzes of worldwide inhaled antibiotic prescriptions for Pseudomonas aeruginosa

Objectives: P. aeruginosa (PA) rates among people with CF (pwCF) have decreased in the last decade. As the health of pwCF has improved, a reduction in inhaled antibiotic (iAB) use is feasible. The aim is to characterize rates of different PA infection status and iAB prescriptions over time in different countries. Here we present study design and initial data from the US. Outcomes and iAB-related side effects will also be evaluated.